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Purpose: To study phenotype-genotype correlation in patients who have retinoma, which is a benign tumor resembling
the post irradiation regression pattern of retinoblastoma (RB).
Methods: We selected patients who had retinoma and positive family history for RB and patients who had retinoma in
one eye and either retinoma or RB in the other eye. The study included 22 patients with available DNA: 18 from 11
families and four sporadic cases. DNA was extracted from peripheral blood leukocytes. The RB1 gene was screened by
DHPLC and direct sequencing of the promoter and all the exons.
Results: We identified 17 occurrences of 11 distinct germline mutations in two sporadic and in 15 familial cases (nine
families). The 11 identified mutations were located in exons 1, 10,11,13,14, and 19 to 23. Four of the identified mutations
were not previously reported, including g.64407delT, g.153236A>T, g.156743delTCTG, and g.162078delA. Eight out
the 11 mutations were truncating and three were nontruncating (missense). There was no correlation between the type of
mutation and the number of tumor foci per eye (RB or retinomas). Highly heterogeneous intrafamilial expressivity was
observed.
Conclusions: To our knowledge, this study is the largest series of mutations of consecutive retinoma patients. The present
data suggest that the type of inherited mutations underlying retinoma is undistinguishable from RB related ones, i.e.,
largely dominated by truncating mutants. This finding is in contrast with the RB1 genotypic spectrum of mutations
associated with low-penetrance RB, i.e., nontruncating mutants. The molecular mechanism underlying low-penetrance
and attenuated expressivity (retinomas) appeared to be distinct.
Mutations of the RB1 gene can result in either malignant
retinoblastoma (RB; OMIM 180200) or benign retinoma [1].
Retinoma mimics the postirradiation regression pattern of RB
[1-4]. On histology, necrosis and mitoses are absent in contrast
with  RB  [5].  According  to  Knudson’s  observation,  both
alleles of the RB1 gene must be inactivated to develop a tumor
[6]. Hereditary germline mutations account for 40% of cases
and nonhereditary somatic mutations for the remaining 60%
[7]. For hereditary cases, mode of inheritance is autosomal
dominant; 90% of germline-mutation carriers develop RB or
retinoma  (high  penetrance)  with  most  of  them  presenting
multiple  tumors  in  both  eyes  (high  expressivity).
Nevertheless,  low  penetrance  is  observed  when  germline
mutation carriers do not develop RB and reduced expressivity
when only unilateral RB or retinoma occurs [8,9]. To better
describe  low-penetrance  RB  families  with  regard  to  both
penetrance and expressivity, Lohmann et al. [9] introduced
the disease-eye ratio (DER), which is the ratio of the number
of eyes containing tumors to the number of mutation carriers
in a family. Typically, diseased-eye ratios are less than 1.0 in
low-penetrance families and 1.5 or greater in full-penetrance
families [9].
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In 70% of RB cases loss of the wild-type allele, or loss of
heterozygosity  happens  through  mitotic  recombination  or
nondisjunction with or without concomitant duplication of the
mutated chromosome [10]. If the predisposing mutation is
truncating, one could expect that loss of heterozygosity would
lead to complete loss of functional protein and thus to RB with
high penetrance and expressivity [8,9,11,12]. In contrast, the
molecular  basis  of  low-penetrance  RB  is  dominated  by
nontruncating mutations [8,9,11,12]. Functionally, the RB1
mutations causing low-penetrance RB were shown either to
reduce  the  level  of  expression  of  normal  RB1  protein  or
produce a mutant RB1 protein that is only partially inactivated
[8,9]. However, recent insights strongly call into question this
assumption with the report of a chain-terminating mutation in
RB1 exon 1 in a large low-penetrance family with unilateral
RB and retinoma [13].
In this report, we correlate the clinical features of 17
retinoma patients to their underlying RB1 germline mutations.
Results are discussed in light of the recent advances regarding
the molecular basis of RB oncogenesis.
METHODS
The study was conducted in accordance to the tenets of the
Declaration of Helsinki. Out of more than 500 patients with
RB and their first-degree relatives treated between 1964 and
2008, we selected patients who had retinoma and a positive
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771family history of RB or patients who had retinoma in one eye
and either RB or retinoma in the other eye. Patients were
referred to us either from university eye clinics and private
Swiss practitioners or from neighboring European countries.
All patients were examined and treated at the Retinoblastoma
Clinic  of  the  Jules-Gonin  Eye  Hospital,  Lausanne,
Switzerland.  All  patients  and  their  first-degree  relatives
underwent full ophthalmic examination and were documented
by fundus photographs and ultrasonography. Fluorescein and
indocyanine angiography was performed in selected patients.
Previously  described  diagnostic  criteria  for  retinoma  and
phthisis were used to identify the retinoma subpopulation
TABLE 1. PRIMERS AND PCR CONDITIONS.
Region Primer                       Sequence 5′-3′
Amplicon                            Annealing
     [bp]                                      [°C]
promoter PromF CTGGACCCACGCCAGGTTTC 340 61
PromR GTTTTGGGCGGCATGACGCCTT
RB exon 1 1F CCGGTTTTTCTCAGGGGACGTTG 340 56.4
1R TTGGCCCCGCCCTACGCACAC
RB exon 2 2F CTATTGAAACAAGTATGTACTG 331 54.3
2R GGGTAATGGAATTATTATTAGC
RB exon 3 3F CAGTTTTAACATAGTATCCAG 281 52.8
3R AGCATTTCTCACTAATTCAC
RB exon 4 4F GTAGTGATTTGATGTAGAGC 305 55
4R CCCAGAATCTAATTGTGAAC
RB exon 5 5F GCATGAGAAAACTACTATGAC 194 54.3
5R CTAACCCTAACTATCAAGATG
RB exon 6 6F CACCCAAAAGATATATCTGG 222 54.3
6R ATTTAGTCCAAAGGAATGCC
RB exon 7 7F CCTGCGATTTTCTCTCATAC 256 55
7R ATGTTTGGTACCCACTAGAC
RB exon 8 8F AGTAGTAGAATGTTACCAAG 380 50.8
8R TACTGCAAAAGAGTTAGCAC
RB exon 9 9F TGCATTGTTCAAGAGTCAAG 222 56
9R AGTTAGACAATTATCCTCCC
RB exon 10 10F TCTTTAATGAAATCTGTGCC 291 56
10R GATATCTAAAGGTCACTAAG
RB exon 11 11F GAGACAACAGAAGCATTATAC 245 54.2
11R CGTGAACAAATCTGAAACAC
RB exon 12 12F GGCAGTGTATTTGAAGATAC 310 52.5
12R AACTACATGTTAGATAGGAG
RB exon 13 13F CTTATGTTCAGTAGTTGTGG 342 54.3
13R TATACGAACTGGAAAGATGC
RB exon 14 14F GTGATTTTCTAAAATAGCAGG 212 58.9
14R TGCCTTGACCTCCTGATCTG
RB exon 15+16 15/16F CAATGCTGACACAAATAAGG 366 55
15/16R AGCATTCCTTCTCCTTAACC
RB exon 17 17F AAAAATACCTAGCTCAAGGG 339 56
17R TGTTAAGAAACACCTCTCAC
RB exon 18 18F TGTACCTGGGAAAATTATGC 340 56.4
18R CTTTATTTGGGTCATGTACC
RB exon 19 19F ATAATCTGTGATTCTTAGCC 273 56
19R AAGAAACATGATTTGAACCC
RB exon 20 20F AAAGAGTGGTAGAAAAGAGG 335 56.4
20R CAGTTAACAAGTAAGTAGGG
RB exon 21 21F AAACCTTTCTTTTTTGAGGC 328 54
21R TACATAATAAGGTCAGACAG
RB exon 22 22F TAATATGTGCTTCTTACCAGTC 313 56
22R TTTAATGTTTTGGTGGACCC
RB exon 23 23F ATCTAATGTAATGGGTCCAC 287 54.2
23R CTTGGATCAAAATAATCCCC
RB exon 24 24F GAATATAGTTTGTCAGTGGTTC 273 52 53
24R GTGTTTGAATAACTGCATTTGG
RB exon 25 25F GGTTGCTAACTATGAAACAC 297 54.2 55
25R AGAAATTGGTATAAGCCAGG
RB exon 26 26F AGTAAGTCATCGAAAGCATC 209 52.8
26R AACGAAAAGACTTCTTGCAG
RB exon 27 27F CGCCATCAGTTTGACATGAG 237 54.2
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772[1]. Eight patients for whom DNA was not available were
excluded from this study. Informed consent was obtained
from all patients or parents to draw blood and perform genetic
analysis. A total of 22 patients were selected and screened for
RB1 mutations. Charts were reviewed for specific clinical
features such as age at diagnosis, tumor type (RB/retinoma),
and number of tumor foci per eye. The number of RB foci
could not be determined in all cases except one, which had a
diffuse form of RB, because patients had been enucleated
elsewhere in their childhood and we did not have access to the
clinical or histopathological data. DER was calculated for
each family.
DNA was extracted from blood leukocytes and used for
PCR amplification. Genetic analysis was performed at the
Institut de Recherche en Ophtalmologie. Previously described
denaturing  high-performance  liquid  chromatography
(DHPLC) [14] and sequencing were used. Amplification was
performed  in  a  thermal  cycler  (GeneAmp  9700;  Applied
Biosystems, Foster City, CA), in a total volume of 30 μl. Each
polymerase chain reaction (PCR) contained 100 ng genomic
DNA, 0.9 nanomoles of each primer, and 15 μl master mix 2X
(Qiagen,  Hombrechtikon,  Switzerland),  with  or  without
betaine. Reactions were subjected to 35 cycles of 94 °C for 1
min, annealing at the specific temperature for 1 min, 72 °C for
1 min, and a final extension step at 72 °C for 10 min. Sequence
of primers and PCR conditions are presented in Table 1. After
PCR  amplification,  products  were  screened  for  mutations
using DHPLC on a WAVE system (Transgenomic, Crewe,
Cheshire, UK). Buffer contained 0.1 M triethylammonium
acetate (TEAA, Transgenomic). Buffer B contained 0.1 M
TEAA and 25% acetonitrile HPLC grade (Sigma-Aldrich,
Suffolk, UK). The flow rate was set at 1.5 ml/min and the
Buffer B gradient increased by 5% per minute for 2 min. The
optimum  temperature  was  determined  by  the  Wavemaker
software (Transgenomic) for each DNA fragment, and a time
shift  was  applied  as  needed  [11].  When  multiple  melting
domains were established, each domain was analyzed at the
appropriate temperature. Initial Buffer B concentrations and
temperatures  for  each  fragment  are  listed  Table  1.  PCR
fragments displaying DHPLC abnormal retention times were
further sequenced on both strands using ABI Dye Terminator,
version  1  or  3,  in  a  final  reaction  volume  of  10  μl,  and
electrophoresed on a 3130XL ABI genetic analyzer (Applied
Biosystems).  Sequences  were  aligned  using  the
Chromasversion 2.23 (Technelysium, Tewantin, Australia).
Screening for large deletions was performed by haplotype
analysis  using  RB1  flanking  microsatellites  D13S161,
S13S164, D13S153, D13S1307, and D13S273. One primer
was fluorescently labeled, and the product was separated on
an automated sequencer (ABI XL3100; Applied Biosystems).
RESULTS
Out of the 22 selected patients, 18 were familial from 11
families and four were sporadic. Out of the 18 familial cases,
we identified mutations in 15 cases, which were from nine
families, and we found mutations in two of the four sporadic
cases.  Thus,  we  had  11  index  cases  in  total  with  proven
germline mutations. Patient clinical features and mutation
descriptions are detailed in Table 2.
Median age at diagnosis was 30.8 years (range 8 months
to 62 years). Mean number of retinoma foci per eye was
1.88±1.5. Four of the identified mutations were not previously
reported (Table 2).
DISCUSSION
We  studied  22  patients  with  retinomas  and  detected  RB1
mutations in 17 (15 familial cases and in 2 sporadic) of them.
The 15 familial cases belonged to nine families that were not
low-penetrance ones (DER 1.1 to 2). In accordance with the
results of Sanchez-Sanchez et al. [13], the observation of
retinoma with predisposing nonsense germline mutation does
not support the hypothesis that truncating mutations do not
cause retinoma. Indeed, truncating mutations were found in
70% of retinoma patients in this study. We tried to determine
if a certain type of mutation could cause higher expressivity
leading to multiple tumor foci in each eye, but there was no
correlation between the type of mutation and the number of
tumor foci per eye (RB or retinoma). In our cohort most
mutations  were  either  nonsense  mutations,  duplication  or
deletions. Although we did not analyze the consequences of
the observed mutations at the RNA level, we can reasonably
assume that they represent truncating mutations. The case of
the  two  remaining  mutations,  R46K  and  E737D,  is  more
complicated. They could represent true missense mutations or
could affect splicing of the nearby intron. Their pathogenicity
is  not  questionable,  as  they  have  been  reported  to  cause
bilateral  RB  [15].  We  have  previously  described  the
L42RfsX25  mutation  located  in  exon  1  [11].  Alternative
translation might be the mechanism by which different levels
of expressivity are present within this family (F1, Figure 1).
In contrast with the family studied by Sanchez-Sanchez
[13],  all  nine  families  in  our  series  had  DER  above  1.0,
suggesting absence of low-penetrance. That the mean number
of retinoma foci per eye was 1.88 indicates a relatively high
level of expressivity. Furthermore, we observed that the same
truncating mutation located in exon 11 and 23 led in Family
4  and  9  respectively  (Figure  2)  to  highly  heterogeneous
expressivity ranging from the most severe bilateral RB to
bilateral retinoma. This occurrence has not previously been
described in association with severe truncating mutations.
Notably, that the predisposing mutation was located at the
carboxyl-terminus of the RB1 gene (Family 9) suggests that
another mechanism than alternative translation initiation may
be  involved.  Unfortunately,  in  none  of  the  families  with
truncating mutations could we perform functional analysis to
determine the level of activity of the protein products. To the
best of our knowledge, this is the first report focusing on
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774germline mutations in retinoma cases. That we did not detect
mutations in two families and two sporadic cases might be due
to the technology applied that would not detect copy number
changes of exons or most mosaicism. However, the 73% of
RB1 mutations (11 mutations found in 15 participants who had
bilateral or familial RB) detected by the technologies applied
suggests  that  the  spectrum  of  mutations  associated  with
retinoma is the same as for RB. Further work is needed in
collaboration with other laboratories to use other mutation
screening technologies to identify mutations in the remaining
cases  and  to  analyze  the  consequences  of  the  observed
mutations at the RNA level. This is beyond the intended scope
of  the  present  work.  Although  no  statistical  analysis  was
possible in this study, in accordance with other published
series  [4,16],  we  propose  that  retinoma  should  not  be
considered  a  form  of  attenuated  expressivity  [17-22],  but
rather  the  result  of  variable  expressivity  occurring  in  a
penetrance independent manner.
Gallie et al. [23] have hypothesized that the stage of cell
maturation  at  which  the  second  RB1  mutation  occurs  is
determinant for the phenotype expression. We observed one
case  in  this  series,  Patient  11,  who  underwent  malignant
transformation  of  his  retinoma,  at  an  adult  age.  This
observation has been previously reported by others [2,4,23,
24] and may support the stage of cell maturation theory with
the understanding that a primitive cell could have remained
latent for many years before becoming activated in the eye of
an  adult  [23].  Another  mechanism  has  been  proposed  to
understand attenuated expressivity represented in this study
by  retinoma.  Recent  histopathological  analysis  of  eyes
enucleated for RB showed retinoma tumors adjacent to both
normal  retina  and  RB  tumors  in  up  to  15.6%  (20/128),
suggesting clonal progression from a normal cell to a benign
one and finally to a malignant cell [16]. Other researchers have
[16] reported molecular evidence of this clonal progression,
showing that retinomas and RBs were homozygous null for
RB1,  could  share  the  same  mutation  of  whatever  class,
including  stop  codon,  and  that  retinomas  expressed
senescence proteins maintaining them in an arrested state.
Retinomas  displayed  genomic  changes  such  as  gain  of
oncogenes and genomic instability to a lesser degree than RB,
which is thought to develop by escaping the senescence state
of  retinomas  [16].  This  hypothesis  of  increasing  genomic
instability for the development of RB is in accordance with
the results we present. Unfortunately, we were not able to
study the type of the second-hit mutation, which might be
determinant, too, in cell destiny.
Conclusions: RB development understanding remains a
challenging but mandatory task due to the life-threatening
complications  it  can  induce.  Its  causative  gene,  RB1,  has
opened the way to the two-hit theory [6], the limitations of
which  have  been  highlighted  by  the  study  of  retinoma,  a
benign tumor. For a long time, retinoma has been considered
to be part of the low-expressivity as well as low-penetrance
Figure  1.  Pedigree  of  Family  1  and
Family 2. Pedigree of the Family 1 in
which  the  L42RfsX25  truncating
mutation  segregates  is  presented.
Alternative  translation  might  be  the
mechanism by which different level of
expressivity  are  present  within  this
family  ranging  from  bilateral  RB  to
unilateral retinomas. In Family 2 which
includes an unaffected R46K mutation
carrier, the level of expressivity is even
lower.  This  mutation  has  been
previously  reported.  Solid  black
symbols  represent  bilateral
retinoblastoma  (RB).  Half  black
symbols represent unilateral RB. Solid
gray  symbols  represent  bilateral
retinoma. Half gray symbols represent
unilateral retinoma. The slashed symbol
represents  deceased  individual,  and
symbol with a black dot represents an
unaffected mutation carrier.
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775presentation and thought to be caused by less severe inherited
mutations. We have shown in this series that even severe
inherited mutations segregating in families with bilateral RB
patients can also cause retinoma. Recently, it has been shown
that  RB  emerges  from  retinoma  after  accumulation  of
genomic  changes,  whereas  retinoma  develops  after
homogeneous  loss  of  RB1  [16].  Thus,  what  we  used  to
consider as low or attenuated expressivity should be revisited
as a step in the cell pathway to malignant tumor development.
Genetic  counseling,  treatment,  and  follow-up
recommendations may highly be influenced by such advances
in RB and retinoma development understanding.
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